Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease

NCT04519684
View directory record Official record
Conditions
Ileal Pouch, Crohn Disease
Interventions
Mesenchymal stem cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Not listed Early Phase 1 Interventional

Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery

NCT03042091
View directory record Official record
Conditions
Colorectal Neoplasms, Diverticulitis, Inflammatory Bowel Diseases, Surgical Site Infection
Interventions
Polyethylene Glycol, Neomycin, Metronidazole Hydrochloride, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
19 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 25, 2026, 6:16 AM EDT
Completed No phase listed Observational Results available

Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis

NCT02438410
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Disease, IBD
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Not applicable Interventional Results available

Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome

NCT04542018
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
a low FODMAP diet for 4 weeks
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)

NCT01692743
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Home Monitoring
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

NCT03029143
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
44
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Pablo, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 25, 2026, 6:16 AM EDT
Not yet recruiting Early Phase 1 Interventional

Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT07238790
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), Diarrhea
Interventions
MITI-001 administration
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 1 Interventional

Protein and Energy Metabolism in Pediatric Crohn's Disease

NCT00583232
View directory record Official record
Conditions
Crohn's Disease, Protein Metabolism, Energy Metabolism
Interventions
Stable isotope infusions
Drug
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

NCT01277666
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
48
States / cities
Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 25, 2026, 6:16 AM EDT
Withdrawn Not applicable Interventional

Reducing Problematic Substance Use in Youth With Chronic Medical Conditions

NCT01709201
View directory record Official record
Conditions
Alcohol Abuse, Drug Abuse
Interventions
Brief Intervention
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis

NCT07686081
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Ponesimod, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chula Vista, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 3 Interventional

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT00552565
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rezular 15mg, Placebo, Rezular
Drug
Lead sponsor
AGI Therapeutics, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2009 · Synced Oct 25, 2026, 6:16 AM EDT
Recruiting Not applicable Interventional

IBS Skin Patch Test Food Allergy Study

NCT06288672
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
True avoidance diet, Sham avoidance diet
Other
Lead sponsor
IBS-80, LLC
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
North Wales, Pennsylvania • Barboursville, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 25, 2026, 6:16 AM EDT
Terminated Phase 3 Interventional

A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

NCT02849951
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LT-02, LT-02 Placebo
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 25, 2026, 6:16 AM EDT
Suspended Not applicable Interventional

Adjunctive Treatment With Vitamin D3 in Patients With Active IBD

NCT04225819
View directory record Official record
Conditions
IBD, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Vitamin D3 Deficiency
Interventions
Vitamin D3, Placebo
Dietary Supplement · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Results available

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

NCT02019602
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions
Blood sampling from mother, Blood sampling from infant, Blood sampling from umbilical cord, Certolizumab Pegol
Procedure · Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Oklahoma City, Oklahoma • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412
View directory record Official record
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Ulcerative Colitis

NCT00410410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
abatacept (ABA), placebo, abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

NCT02522780
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Little Rock, Arkansas • Murrieta, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Phase 3 Interventional

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

NCT02914535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
1,173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis

NCT05180279
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
7-day sleep lab
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Not applicable Interventional Results available

Evaluation of PillCam® Express Capsule Endoscopy Delivery System

NCT01088646
View directory record Official record
Conditions
Small Bowel Disease, Inflammatory Bowel Disease
Interventions
PillCam® Express Capsule Endoscopy Delivery System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
2 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Huntsville, Alabama • Montgomery, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 25, 2026, 6:16 AM EDT
Completed Not applicable Interventional

Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)

NCT00829218
View directory record Official record
Conditions
Irritable Bowel Syndrome, Fibromyalgia
Interventions
Glutamate additive-free diet, Placebo diet
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 25, 2026, 6:16 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03759288
View directory record Official record
Conditions
Crohn's Disease, IBD
Interventions
Brazikumab low dose, Brazikumab high dose, Humira®, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 6:16 AM EDT